About us
ApconiX was formed with the objective to give companies and organisations of all sizes, access to the breadth and depth of nonclinical safety expertise generally only available to large pharma. Our areas of expertise include cardiac and CNS electrophysiology, target and modality safety science and all aspects of project toxicology and DMPK support.
The consultancy group provides flexible nonclinical toxicology and DMPK support to discovery and development projects, including study outsourcing and monitoring, backed up with an extensive team of world renowned subject matter experts.
Our lab conducts cardiac ion channel screening (hERG and CiPA) using the latest generation automated platforms and manual patch clamp technology. We have also developed an in vitro CNS assay to assess seizure liability (iSLA®). We continue to work with our clients to expand our areas of interest in relevant fields, including efficacy screening.
The ApconiX Safety Science Team combines toxicology expertise and advanced data science, offering customized Acuity® target safety assessments (TSAs) as well as modality and asset focused evaluations. Our safety scientists have many years of experience in problem solving and investigative toxicology available to our clients.
Drug research and development is a truly global endeavour. 60% of our work is with countries outside of the UK and in the last three years we have achieved both a Queen’s and a King’s Award for International Trade.
ApconiX has a unique business model that works for clients all over the world who require access to experienced and credible drug safety scientists for anything from just an hour or two, to multi-year support. This is true of our client and potential client companies of any size in any location.
We have an extensive range of colleagues and collaborators in the international R&D community. Our high-profile presence in international drug research and development has led to many cutting-edge scientific collaborations with leaders in the field from industry, academia and government. These collaborations are driving the field forward in key areas such as new drug modalities, immune oncology drug safety and early detection of neurological effects.
We have formed alliances with key international and global Contract Research Organisations (CROs) with whom we work on behalf of our clients.
ApconiX Evolution Timeline
Our Awards
